EHN response to the Commission Consultation on the Revision of the EU general pharmaceuticals legislation

December 20th 2021

EHN submitted its views on the European Commission's public consultation aimed at evaluating the existing general pharmaceutical legislation on medicines for human use to support its revision to ensure a future-proof and crisis-resistant medicines regulatory system.

Click here to download EHN's submission.

EHN's input calls for modernising the regulatory framework to foster patient-centered innovation for cardiovascular patients. It builds on previous EHN contributions and calls in the Blueprint for EU Action on CVD.